Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Biotechnology

Healthcare
$8.86 +2.49%

+$0.22 today

Market cap
$595.76M
Beta
1.48
P/E (TTM)
-8.6
EPS (TTM)
-$0.74
52W Low $5.82High $12.86

Volume 0.16M

Average 0.05M

EPRX.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $2.25M rose 50.9% year over year, behind the +143.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 62.3% from the prior quarter. Over 3 fiscal years it compounded at +84.7% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +50.9% toward the trailing-twelve-month pace of +143.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.25M-62.3% QoQ
Last fiscal yearDec 2025
$9.04M+180.4% YoY
LTMMar 2026
$9.67M+143.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.9%——
1 year+180.4%——
3-year CAGR+84.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

Mixed currencies · from the cash flow

Latest · FY2025
9.04M USD
Year-over-year change
+180.4%

Stock-Based Compensation vs competitors

How EPRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +143.3% is the 3rd highest of 8, against a peer median of +54.8%.
  • Over three fiscal years its annual growth of +84.7% compares with a peer median of -8.3%.
EPRX.TO Competitors
Stock-Based Compensation for EPRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$9.67M USD+143.3%+84.7%—
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$7.23M USD+54.8%+18.6%14.1%
PRN.TOProfound Medical Corp.LTM Mar 2026$5.55M USD+98.0%+9.0%29.6%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$5.06M CAD+220.3%-44.8%1.6%
TSND.TOTerrAscend Corp.LTM Mar 2026$4.38M USD-55.0%-25.6%1.7%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$3.45M CAD-36.6%—1.3%
DR.TOMedical Facilities CorporationLTM Mar 2026$246K USD+228.0%—0.1%
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$0 CAD-100.0%——
Peer median (excluding EPRX.TO) —+54.8%-8.3%1.6%

Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(23.37M)(23.26M)(28.15M)(25.74M)(38.61M)
Depreciation & Amortization111.53K200.24K117.1K235.25K241.88K
Deferred Income Tax1.2M0000
Stock-Based Compensation4.21M1.43M1.06M3.22M9.04M
Change in Working Capital(211.43K)2.07M4.76M(6.76M)(726.19K)
Accounts Receivables190.89K310.06K(105.39K)(101.39K)(439K)
Inventory0(1.32M)(435.12K)00
Accounts Payables01.32M435.12K(714.88K)2.4M
Other Working Capital(402.32K)1.76M4.87M(5.95M)(2.69M)
Other Non-Cash Items3.41M776.17K1.51M(944.03K)1M
Operating Cash Flow(14.64M)(18.78M)(21.02M)(29.99M)(29.05M)
Capital Expenditures(431.67K)(308.37K)(55.25K)(104.23K)(599.26K)
Acquisitions (Net)0310039.82K0
Purchases of Investments(9M)(310)000
Sales of Investments09.01M000
Other Investing Activities(5.02M)310027.81K0
Investing Cash Flow(14.45M)8.7M(73.2K)(75.16K)(599.26K)
Debt Repayment12.17M(97.49K)(108.75K)(9.14M)0
Common Stock Issued29.67M10.64M11.96M54.56M77.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(87.7K)(87.7K)9.11M363.06K0
Financing Cash Flow49.92M13.52M20.96M45.78M77.39M
Effect of Forex Changes(81.63K)396.83K821.4K(1.96M)(1.99M)
Net Change in Cash20.74M3.84M1.08M13.76M45.75M
Free Cash Flow(15.07M)(19.08M)(21.09M)(30.1M)(29.65M)

Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.